Diagnostics for the Real World, Ltd.

Diagnostics for the Real World (DRW) develops decentralized point-of-care (POC) molecular diagnostic systems for use in clinical and non-laboratory settings. The company's flagship platform, SAMBA, is a molecular diagnostic machine designed to deliver rapid pathogen detection at the site where patients are seen, enabling prompt clinical intervention. DRW's SAMBA platform performs multiplex molecular testing for respiratory pathogens including COVID-19, Influenza A/B, and RSV. The system is engineered for simplicity and high performance, supporting "one sample, one test" workflows in hospitals, laboratories, and non-laboratory environments. The company has received regulatory approval in multiple markets, including New Zealand, and maintains a distributed network of service partners and distributors globally. DRW emphasizes decentralized testing infrastructure and rapid turnaround diagnostics as core capabilities. The SAMBA II represents a breakthrough in POC molecular diagnostics and has achieved recognition in major institutional collections and exhibitions. The company provides service and training support, maintains open-access testing programs, and publishes clinical evidence. Manufacturing and regulatory credentials are consistent with EU and international diagnostic standards.